Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Hyperlipidemia is a chronic metabolic disorder characterized by elevated lipid and lipoprotein levels due to impaired lipid metabolism, increasing cardiovascular risk. According to Jia Wei et al., 2024, prevalence data indicate about 28 million adults in the United States have total cholesterol levels ≥240 mg/dl, doubling ASCVD risk versus normal levels. Current therapies include statins, ezetimibe, PCSK9 inhibitors, and emerging RNA-based therapies and gene therapies targeting lipid regulation pathways. As per hyperlipidemia pipeline analysis by Expert Market Research, increasing focus on precision medicine, monoclonal antibodies, and next-generation lipid-lowering drugs is expected to support growth in coming years.
-
Major companies involved in the hyperlipidemia pipeline analysis include Qilu Pharmaceutical Co., Ltd., Verve Therapeutics, Inc., Innovent Biologics (Suzhou) Co. Ltd., and others.
-
Leading drugs currently in the pipeline include QLC7401, IBI306, VERVE-201, and others.
-
Advancing PCSK9 inhibitors, siRNA therapies, and novel combination lipid-lowering agents are driving pipeline growth, supported by rising clinical trials focused on improved LDL-C reduction and cardiovascular risk management.
Report Coverage
The Hyperlipidemia Pipeline Analysis Report by Expert Market Research gives comprehensive insights into hyperlipidemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hyperlipidemia. The Hyperlipidemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hyperlipidemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hyperlipidemia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hyperlipidemia.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Hyperlipidemia Pipeline Outlook
Hyperlipidemia is a metabolic disorder characterized by elevated levels of hyperlipidemia lipids, including LDL cholesterol and triglycerides, in the bloodstream. It occurs due to genetic factors, unhealthy diet, sedentary lifestyle, obesity, diabetes, or impaired lipid metabolism, leading to plaque buildup in arteries and increased risk of cardiovascular disease such as heart attack and stroke.
Hyperlipidemia treatment includes lifestyle modification, statins, PCSK9 inhibitors, bile acid sequestrants, and cholesterol absorption inhibitors to reduce LDL cholesterol and prevent cardiovascular complications, supported by diet, exercise, and weight management strategies. Following the July 2025 regulatory update, Novartis announced FDA approval expanding inclisiran (Leqvio) for first-line monotherapy in hyperlipidemia, targeting LDL cholesterol reduction via PCSK9 inhibition. This pipeline advancement strengthens long-acting RNA-based therapies, improving adherence and reducing cardiovascular disease risk in high-risk patients.
Hyperlipidemia Epidemiology
The data indicates a rising global burden of lipid metabolism disorders contributing to cardiovascular risk. According to Jia Wei et al., 2024, hyperlipidemia is an independent risk factor for atherosclerosis, myocardial infarction, and coronary heart disease, with about 28 million adults in the United States having cholesterol levels above 240 mg/dL, significantly increasing atherosclerotic cardiovascular disease (ASCVD) risk. According to Nikil Niva J et al., 2025, prevalence in India ranges from 10–15 percent in rural areas and 25-30% in urban regions, with diabetes and hypertension as key contributing factors. Demand for lipid-lowering therapies continues to grow globally.
Hyperlipidemia – Pipeline Therapeutic Assessment
This section of the report covers the analysis of hyperlipidemia drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase 1)
- Preclinical and Discovery Stage Products
By Drug Class
The hyperlipidemia pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Oligonucleotide Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Hyperlipidemia Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III, with 35%, covers a major share of the total hyperlipidemia clinical trials, driving strong approval potential and market expansion. Phase II with 27% supports efficacy validation with growing clinical momentum. Phase I with 19% enables safety profiling, while early phase I with 9% initiates innovation. Phase IV with 10% enhances real-world evidence and therapeutic adoption.
Hyperlipidemia Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the hyperlipidemia pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and oligonucleotide therapies. The hyperlipidemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hyperlipidemia. Immune-based and RNA interference (RNAi)-based therapies are emerging as innovative approaches in the hyperlipidemia pipeline, targeting key lipid-regulating genes to improve cardiovascular outcomes. For instance, PCSK9 inhibitors and APOC3-targeting RNAi therapeutics are under investigation to reduce LDL-cholesterol and triglycerides. Moreover, dual gene-silencing RNAi molecules such as ARO-DIMER-PA represent next-generation candidates designed to simultaneously lower atherogenic lipoproteins, thereby addressing residual cardiovascular risk in mixed hyperlipidemia patients.
Hyperlipidemia Clinical Trials – Key Players
The EMR report for the hyperlipidemia pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hyperlipidemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hyperlipidemia clinical trials:
- Qilu Pharmaceutical Co., Ltd.
- Verve Therapeutics, Inc.
- Innovent Biologics (Suzhou) Co. Ltd.
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Ionis Pharmaceuticals, Inc.
- Merck Sharp & Dohme LLC
- Regeneron Pharmaceuticals
- AstraZeneca
- Kowa Company, Ltd.
- CorrectSequence Therapeutics Co., Ltd.
Hyperlipidemia – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hyperlipidemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hyperlipidemia drug candidates.
Drug: QLC7401
QLC7401 is a PCSK9-targeting small interfering RNA (siRNA) therapy being administered via subcutaneous injection and is currently being developed by Qilu Pharmaceutical Co., Ltd. in collaboration with Ribo using the proprietary RiboGalSTAR delivery system. The Phase III, randomized, double-blind, placebo-controlled study is examining the efficacy, safety, and immunogenicity of QLC7401 in patients with primary hypercholesterolemia or mixed hyperlipidemia with poorly controlled LDL-C on optimized lipid-lowering therapy. The drug is designed to sustainably reduce LDL-C through hepatic inhibition of PCSK9 expression, enabling long-acting lipid control. The study is estimated to complete in March 2028.
Drug: IBI306
IBI306 (tafolecimab, SINTBILO®) is being evaluated in a Phase III, multicenter, randomized, double-blind, placebo-controlled clinical study sponsored by Innovent Biologics (Suzhou) Co. Ltd. It is a recombinant fully human IgG2 monoclonal antibody that is acting by inhibiting PCSK9 binding to LDL receptors, thereby enhancing LDL-C clearance from the bloodstream. The study examines the efficacy and safety of IBI306 monotherapy in patients with non-familial hypercholesterolemia and mixed hyperlipidemia. It is being administered via subcutaneous injection with long-acting dosing potential. The trial enrolls approximately 198 participants, with study completion expected by February 2027, while evaluating lipid-lowering outcomes over a 12-week treatment period.
Drug: VERVE-201
VERVE-201 is currently being evaluated in a Phase 1b, open-label, single-ascending dose study sponsored by Verve Therapeutics, Inc. The study is examining the safety, tolerability, and pharmacodynamic profile of VERVE-201 in patients with refractory hyperlipidemia, while also assessing its ability to lower LDL-C and triglycerides. The drug is a base-editing therapy designed to inactivate the ANGPTL3 gene in the liver. It is being administered via an investigational GalNAc-LNP delivery system targeting hepatic uptake. The study is expected to be completed by December 2027, while continuously evaluating its lipid-lowering potential.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Hyperlipidemia Pipeline Insight Report
- Which companies/institutions are leading the hyperlipidemia drug development?
- Which company is leading the hyperlipidemia pipeline development activities?
- What is the current hyperlipidemia commercial assessment?
- What are the opportunities and challenges present in the hyperlipidemia pipeline landscape?
- What is the efficacy and safety profile of hyperlipidemia pipeline drugs?
- Which company is conducting major trials for hyperlipidemia drugs?
- Which companies/institutions are involved in hyperlipidemia collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in hyperlipidemia?
Reasons To Buy This Report
The Hyperlipidemia pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for hyperlipidemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hyperlipidemia collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
